ReGelTec
Phase 1ReGelTec is developing HYDRAFIL, a next generation treatment for degenerative disc disease.
Founded
2015
Focus
Drug DeliveryMedical Devices
About
ReGelTec is developing HYDRAFIL, a next generation treatment for degenerative disc disease.
Funding History
2Total raised: $12.5M
Series A$10MUndisclosedMar 15, 2023
Seed$2.5MMaryland Venture FundJun 15, 2021
Company Info
TypePrivate
Founded2015
LocationBaltimore, United States
StagePhase 1
Contact
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile